Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Microbot Medical ( (MBOT) ).
On January 12, 2026, Microbot Medical reaffirmed its 2025 progress, highlighting FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, the launch of a limited market release, and the first clinical adoption at Emory University Hospital, alongside strengthening its commercial infrastructure, third‑party manufacturing partnerships, teleintervention collaborations, and balance sheet. The company said this foundation positions it to begin a full U.S. market release of LIBERTY in the second quarter of 2026, expand its hospital customer base and procedural use cases, build out international commercial infrastructure, deepen collaborations in teleintervention and autonomous robotics, and continue broadening its patent estate, moves that collectively aim to cement LIBERTY’s position in endovascular robotics and support longer-term growth across peripheral and other interventional specialties.
The most recent analyst rating on (MBOT) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. (Nasdaq: MBOT) is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the first single-use, remotely operated robotic solution for peripheral endovascular procedures, targeting a U.S. market of roughly 2.5 million such interventions annually and supported by a growing global intellectual property portfolio.
Average Trading Volume: 2,309,189
Technical Sentiment Signal: Sell
Current Market Cap: $147.1M
For a thorough assessment of MBOT stock, go to TipRanks’ Stock Analysis page.